Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research

A. Mahindra; M. E. Kalaycio; J. Vela-Ojeda; D. H. Vesole; M. J. Zhang; P. Li; J. R. Berenson; J. M. Bird; A. Dispenzieri; J. L. Gajewski; R. P. Gale; L. Holmberg; S. Kumar; R. A. Kyle; H. M. Lazarus; S. Lonial; J. Mikhael; G. A. Milone; R. Munker; R. Nath; S. Saccaro; L. B. To; D. T. Vogl; B. Wirk; P. Hari

doi:10.1038/leu.2011.312

Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research

A. Mahindra, M. E. Kalaycio, J. Vela-Ojeda, D. H. Vesole, M. J. Zhang, P. Li, J. R. Berenson, J. M. Bird, A. Dispenzieri, J. L. Gajewski, R. P. Gale, L. Holmberg, S. Kumar, R. A. Kyle, H. M. Lazarus, S. Lonial, J. Mikhael, G. A. Milone, R. Munker, R. NathS. Saccaro, L. B. To, D. T. Vogl, B. Wirk, P. Hari

Research output: Contribution to journal › Article › peer-review

91 Scopus citations

Abstract

There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34% (95% confidence interval (CI), 23-46%) in the autologous group and 20% (95% CI, 10-34%) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61% (95% CI, 48-72%) in the autologous group and 38% (95% CI, 25-53%) in the allogeneic group. Overall survival (OS) at 3 years was 64% (95% CI, 52-75%) in the autologous group and 39% (95% CI, 26-54%) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5% (95% CI, 1-11%) in the autologous group and 41% (95% CI, 28-56%) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.

Original language	English
Pages (from-to)	1091-1097
Number of pages	7
Journal	Leukemia
Volume	26
Issue number	5
DOIs	https://doi.org/10.1038/leu.2011.312
State	Published - May 2012

Funding

The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from AABB; Allos, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US, Inc.; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical, Inc.; Biovitrum AB; BloodCenter of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children’s Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Eisai, Inc.; Genentech, Inc.; Genzyme Corporation; Histogenetics, Inc.; HKS Medical Information Systems; Hospira, Inc.; Kirin Brewery Co., Ltd.; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Nature Publishing Group; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pall Life Sciences; Pfizer Inc; Schering Corporation; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, Inc.; StemSoft Software, Inc.; Sysmex America, Inc.; THERAKOS, Inc.; Vidacare Corporation; ViraCor Laboratories; ViroPharma, Inc.; and Wellpoint, Inc.

Funders	Funder number
Office of Naval Research Naval Academy
U.S. Department of Health and Human Services	N00014-06-1-0704, N00014-08-1-0058
National Heart, Lung, and Blood Institute (NHLBI)
National Childhood Cancer Registry – National Cancer Institute
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...	5U01HL069294, HHSH234200637015C
Health Resources and Services Administration
AMGen
AABB
Allos Therapeutics

Keywords

Primary plasma cell leukemia
overall survival
stem cell transplant

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2011.312

Cite this

Mahindra, A., Kalaycio, M. E., Vela-Ojeda, J., Vesole, D. H., Zhang, M. J., Li, P., Berenson, J. R., Bird, J. M., Dispenzieri, A., Gajewski, J. L., Gale, R. P., Holmberg, L., Kumar, S., Kyle, R. A., Lazarus, H. M., Lonial, S., Mikhael, J., Milone, G. A., Munker, R., ... Hari, P. (2012). Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research. Leukemia, 26(5), 1091-1097. https://doi.org/10.1038/leu.2011.312

@article{aeb4721ae0674758841898f0fb933a1d,

title = "Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research",

abstract = "There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34\% (95\% confidence interval (CI), 23-46\%) in the autologous group and 20\% (95\% CI, 10-34\%) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61\% (95\% CI, 48-72\%) in the autologous group and 38\% (95\% CI, 25-53\%) in the allogeneic group. Overall survival (OS) at 3 years was 64\% (95\% CI, 52-75\%) in the autologous group and 39\% (95\% CI, 26-54\%) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5\% (95\% CI, 1-11\%) in the autologous group and 41\% (95\% CI, 28-56\%) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.",

keywords = "Primary plasma cell leukemia, overall survival, stem cell transplant",

author = "A. Mahindra and Kalaycio, \{M. E.\} and J. Vela-Ojeda and Vesole, \{D. H.\} and Zhang, \{M. J.\} and P. Li and Berenson, \{J. R.\} and Bird, \{J. M.\} and A. Dispenzieri and Gajewski, \{J. L.\} and Gale, \{R. P.\} and L. Holmberg and S. Kumar and Kyle, \{R. A.\} and Lazarus, \{H. M.\} and S. Lonial and J. Mikhael and Milone, \{G. A.\} and R. Munker and R. Nath and S. Saccaro and To, \{L. B.\} and Vogl, \{D. T.\} and B. Wirk and P. Hari",

year = "2012",

month = may,

doi = "10.1038/leu.2011.312",

language = "English",

volume = "26",

pages = "1091--1097",

number = "5",

}

Mahindra, A, Kalaycio, ME, Vela-Ojeda, J, Vesole, DH, Zhang, MJ, Li, P, Berenson, JR, Bird, JM, Dispenzieri, A, Gajewski, JL, Gale, RP, Holmberg, L, Kumar, S, Kyle, RA, Lazarus, HM, Lonial, S, Mikhael, J, Milone, GA, Munker, R, Nath, R, Saccaro, S, To, LB, Vogl, DT, Wirk, B & Hari, P 2012, 'Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research', Leukemia, vol. 26, no. 5, pp. 1091-1097. https://doi.org/10.1038/leu.2011.312

TY - JOUR

T1 - Hematopoietic cell transplantation for primary plasma cell leukemia

T2 - Results from the Center for International Blood and Marrow Transplant Research

AU - Mahindra, A.

AU - Kalaycio, M. E.

AU - Vela-Ojeda, J.

AU - Vesole, D. H.

AU - Zhang, M. J.

AU - Li, P.

AU - Berenson, J. R.

AU - Bird, J. M.

AU - Dispenzieri, A.

AU - Gajewski, J. L.

AU - Gale, R. P.

AU - Holmberg, L.

AU - Kumar, S.

AU - Kyle, R. A.

AU - Lazarus, H. M.

AU - Lonial, S.

AU - Mikhael, J.

AU - Milone, G. A.

AU - Munker, R.

AU - Nath, R.

AU - Saccaro, S.

AU - To, L. B.

AU - Vogl, D. T.

AU - Wirk, B.

AU - Hari, P.

PY - 2012/5

Y1 - 2012/5

N2 - There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34% (95% confidence interval (CI), 23-46%) in the autologous group and 20% (95% CI, 10-34%) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61% (95% CI, 48-72%) in the autologous group and 38% (95% CI, 25-53%) in the allogeneic group. Overall survival (OS) at 3 years was 64% (95% CI, 52-75%) in the autologous group and 39% (95% CI, 26-54%) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5% (95% CI, 1-11%) in the autologous group and 41% (95% CI, 28-56%) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.

AB - There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34% (95% confidence interval (CI), 23-46%) in the autologous group and 20% (95% CI, 10-34%) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61% (95% CI, 48-72%) in the autologous group and 38% (95% CI, 25-53%) in the allogeneic group. Overall survival (OS) at 3 years was 64% (95% CI, 52-75%) in the autologous group and 39% (95% CI, 26-54%) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5% (95% CI, 1-11%) in the autologous group and 41% (95% CI, 28-56%) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.

KW - Primary plasma cell leukemia

KW - overall survival

KW - stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=84860778432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860778432&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.312

DO - 10.1038/leu.2011.312

M3 - Article

AN - SCOPUS:84860778432

SN - 0887-6924

VL - 26

SP - 1091

EP - 1097

JO - Leukemia

JF - Leukemia

IS - 5

ER -

Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this